Shanghai, China

Yu Pu

This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yu Pu. Retrieved from https://idiyas.com/inventor/yu-pu-lipgp4cf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yu Pu - Innovator in JAK Inhibitor Development

Introduction

Yu Pu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of JAK inhibitors. His innovative work has led to the creation of a unique salt form and crystal form of a JAK inhibitor, which has important implications for medical treatments.

Latest Patents

Yu Pu holds 1 patent for his invention titled "Salt form and crystal form of JAK inhibitor, preparation method therefor, and use thereof." This patent provides a detailed description of a preparation method for a JAK inhibitor, along with its uses. Notably, the invention includes an X-ray powder diffraction pattern of a crystal form A of the compound, which exhibits characteristic diffraction peaks at specific 2θ angles.

Career Highlights

Yu Pu is associated with Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development in biopharmaceuticals. His expertise in the field has positioned him as a key player in the innovation of therapeutic solutions.

Collaborations

Yu Pu has collaborated with notable colleagues, including Ming Cheng and Yaqi Cao. Their combined efforts contribute to the ongoing research and development initiatives within their organization.

Conclusion

Yu Pu's contributions to the field of JAK inhibitors exemplify the impact of innovative research in pharmaceuticals. His work not only advances scientific knowledge but also holds promise for future medical applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…